SG11202005896WA - Esketamine for the treatment of depression - Google Patents
Esketamine for the treatment of depressionInfo
- Publication number
- SG11202005896WA SG11202005896WA SG11202005896WA SG11202005896WA SG11202005896WA SG 11202005896W A SG11202005896W A SG 11202005896WA SG 11202005896W A SG11202005896W A SG 11202005896WA SG 11202005896W A SG11202005896W A SG 11202005896WA SG 11202005896W A SG11202005896W A SG 11202005896WA
- Authority
- SG
- Singapore
- Prior art keywords
- esketamine
- depression
- treatment
- Prior art date
Links
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 title 1
- 208000020401 Depressive disease Diseases 0.000 title 1
- 229960000450 esketamine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762609504P | 2017-12-22 | 2017-12-22 | |
| US201862663206P | 2018-04-26 | 2018-04-26 | |
| US201862663219P | 2018-04-26 | 2018-04-26 | |
| US201862667406P | 2018-05-04 | 2018-05-04 | |
| US201862675846P | 2018-05-24 | 2018-05-24 | |
| US201862755905P | 2018-11-05 | 2018-11-05 | |
| PCT/US2018/066143 WO2019126108A1 (fr) | 2017-12-22 | 2018-12-18 | Eskétamine pour le traitement de la dépression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202005896WA true SG11202005896WA (en) | 2020-07-29 |
Family
ID=65003585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202005896WA SG11202005896WA (en) | 2017-12-22 | 2018-12-18 | Esketamine for the treatment of depression |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11707440B2 (fr) |
| EP (1) | EP3501542A1 (fr) |
| JP (2) | JP2021506924A (fr) |
| KR (2) | KR20200113197A (fr) |
| CN (2) | CN117531017A (fr) |
| AU (1) | AU2018282466A1 (fr) |
| BR (1) | BR112020012473A2 (fr) |
| CA (1) | CA3086478A1 (fr) |
| IL (1) | IL275482A (fr) |
| JO (1) | JOP20200156A1 (fr) |
| MA (1) | MA47719A (fr) |
| MX (2) | MX2020006650A (fr) |
| PH (1) | PH12020500555A1 (fr) |
| SG (1) | SG11202005896WA (fr) |
| TW (2) | TWI843711B (fr) |
| WO (1) | WO2019126108A1 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20200404A1 (es) | 2013-03-15 | 2020-02-26 | Janssen Pharmaceutica Nv | Composicion farmaceutica de clorhidrato de s-ketamina |
| CA2961208A1 (fr) | 2014-09-15 | 2016-03-24 | Janssen Pharmaceutica Nv | Regimes posologiques specifiques au genotype val66met (snp rs6265) et methodes pour le traitement de la depression |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| CN117531017A (zh) | 2017-12-22 | 2024-02-09 | 詹森药业有限公司 | 用于治疗抑郁症的艾司氯胺酮 |
| KR20210028159A (ko) | 2018-06-27 | 2021-03-11 | 클렉시오 바이오사이언시스 리미티드 | 주요 우울 장애를 치료하는 방법 |
| AU2019352028A1 (en) | 2018-10-05 | 2021-03-11 | Clexio Biosciences Ltd. | Dosage regime of esketamine for treating major depressive disorder |
| MA55218A (fr) * | 2019-03-05 | 2022-01-12 | Janssen Pharmaceuticals Inc | Eskétamine pour le traitement de la dépression |
| AU2020324432A1 (en) * | 2019-08-05 | 2021-10-07 | The Ketamine Research Foundation | Ketamine for the treatment of postpartum symptoms and disorders |
| US20220304950A1 (en) * | 2019-08-28 | 2022-09-29 | Janssen Pharmaceuticals, Inc. | Esketamine for the treatment of patients with major depressive disorder, including suicidality |
| EP4028085A4 (fr) * | 2019-09-13 | 2023-10-04 | Janssen Pharmaceuticals, Inc. | Administration intranasale d'eskétamine |
| TW202135787A (zh) | 2019-12-12 | 2021-10-01 | 比利時商健生藥品公司 | 艾氯胺酮調配物及製備與儲存的方法 |
| EP4084786A1 (fr) | 2019-12-30 | 2022-11-09 | Clexio Biosciences Ltd. | Régime posologique à base d'eskétamine pour le traitement d'un trouble dépressif majeur |
| WO2021137148A1 (fr) | 2019-12-30 | 2021-07-08 | Clexio Biosciences Ltd. | Régime posologique à base d'eskétamine pour le traitement de troubles neuropsychiatriques ou neurologiques |
| WO2022087383A1 (fr) * | 2020-10-22 | 2022-04-28 | Tonix Pharmaceuticals Holding Corp. | Procédés de respect de randomisation pour évaluer la signification d'interventions sur des résultats dans des troubles |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10025A (en) | 1853-09-20 | Improvement in turbines | ||
| CH535201A (de) | 1969-12-19 | 1973-03-31 | Bristol Myers Co | Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren |
| JPS632932A (ja) | 1986-06-23 | 1988-01-07 | Teijin Ltd | 経鼻投与用粉末状組成物 |
| US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| US4994467A (en) | 1989-05-31 | 1991-02-19 | Zimmerman Andrew W | Treating autism and other developmental disorders in children with NMDA receptor antagonists |
| DE4312016A1 (de) | 1993-04-13 | 1994-10-20 | Goedecke Ag | Stabile Ketamin-Lösungen |
| US5543434A (en) | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
| JP4173538B2 (ja) | 1995-02-24 | 2008-10-29 | スチュアート エル ウェグ | 痛みの管理及び解毒のためのケタミンの点鼻及び点眼投与 |
| WO1997007750A1 (fr) | 1995-08-30 | 1997-03-06 | Weg Stuart L | Administration de ketamine pour gerer la douleur et reduire la dependance aux medicaments |
| FR2739294B1 (fr) | 1995-09-29 | 1998-01-16 | Lhd Lab Hygiene Dietetique | Embout nasal de securite |
| DE19619665C2 (de) | 1996-05-15 | 2001-03-08 | Goedecke Ag | Racemattrennung von Ketamin |
| DE19723133A1 (de) | 1997-06-03 | 1998-12-10 | Caideil M P Teoranta Tourmakea | Austragvorrichtung für Medien |
| FR2764807B1 (fr) | 1997-06-18 | 1999-08-20 | Valois Sa | Dispositif de distribution nasale d'un produit fluide ou pulverulent |
| EP1113785B1 (fr) | 1998-07-24 | 2005-04-13 | Seo Hong Yoo | Solutions claires aqueuses avec des acides biliaires |
| US6599883B1 (en) | 1998-10-30 | 2003-07-29 | Nastech Pharmaceutical Company, Inc. | Nasal delivery of xylitol |
| US6176242B1 (en) | 1999-04-30 | 2001-01-23 | Medtronic Inc | Method of treating manic depression by brain infusion |
| US6017961A (en) | 1999-07-08 | 2000-01-25 | Flores; John Anthony | Ketamine and n-butyl-p-aminobezoate in PLO |
| EP1103256A1 (fr) | 1999-11-26 | 2001-05-30 | Claudius Dr. med. Böck | Utilisation de la kétamine pour le traitement de la dysfonction immunitaire neuroendocrine et du psyhosyndrome algogénique |
| EP1328214A4 (fr) | 2000-09-20 | 2009-07-29 | Shahinian Lee Jr | Preparations et medications nasales, inhalables et ophtalmiques locales a conservation spontanee |
| US6881731B1 (en) | 2000-10-23 | 2005-04-19 | Shanbrom Technologies, Llc | Enhancers for microbiological disinfection |
| US7973043B2 (en) | 2002-07-30 | 2011-07-05 | Peter Migaly | Combination therapy for depression, prevention of suicide, and various medical and psychiatric conditions |
| US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| EP2027854A1 (fr) | 2002-11-18 | 2009-02-25 | Yaupon Therapeutics, Inc. | Utilisations analgésiques pour les promédicaments à base de norkétamine et kétamine/norkétamine |
| US7687080B2 (en) | 2002-11-25 | 2010-03-30 | Taraxos Inc. | Treatment of neuropathy |
| US20040214215A1 (en) | 2003-03-07 | 2004-10-28 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
| US8082173B2 (en) | 2003-05-22 | 2011-12-20 | Cecil Kost | Drug sample fulfillment architecture |
| US20040265364A1 (en) | 2003-06-25 | 2004-12-30 | Binnur Ozturk | Neuropathy cream |
| US20050095277A1 (en) | 2003-06-25 | 2005-05-05 | Binnur Ozturk | Neuropathy cream |
| US20060223788A1 (en) | 2005-03-29 | 2006-10-05 | Cathcart Clifton H | Analgesic composition for topical use |
| US7896850B2 (en) | 2005-06-01 | 2011-03-01 | Telefonaktiebolaget L M Ericsson (Publ) | Device for delivering medicament |
| US20060276550A1 (en) | 2005-06-03 | 2006-12-07 | Dileep Bhagwat | Topical compositions of ketamine and butamben and methods of their use |
| EP2012762A4 (fr) | 2006-03-22 | 2010-03-10 | Sinai School Medicine | Administration intra-nasale de ketamine pour traiter la depression |
| WO2007123945A2 (fr) | 2006-04-21 | 2007-11-01 | Aradigm Corporation | Dispositif monodose de distribution intrapulmonaire de médicaments |
| EP2029136A4 (fr) | 2006-05-22 | 2010-01-06 | Vanda Pharmaceuticals Inc | Traitement pour troubles dépressifs |
| DE102007009888A1 (de) | 2007-02-28 | 2008-09-04 | Hermann, Holger Lars, Dr. | Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen |
| WO2008151179A2 (fr) | 2007-06-04 | 2008-12-11 | Auspex Pharmaceuticals, Inc. | Phénéthylamines substituées |
| US8710070B2 (en) | 2008-03-27 | 2014-04-29 | University Of Kentucky Research Foundation | Opioid-ketamine and norketamine codrug combinations for pain management |
| US20110038807A1 (en) | 2009-08-14 | 2011-02-17 | Demitri Papolos | Compositions and methods for treating bipolar disorder |
| US20120225949A1 (en) | 2009-08-14 | 2012-09-06 | Demitri Papalos | Compositions and methods for treating bipolar disorder |
| DK2582366T3 (en) | 2010-06-15 | 2015-12-07 | Gruenenthal Gmbh | A pharmaceutical combination for the treatment of pain. |
| WO2013003669A2 (fr) | 2011-06-30 | 2013-01-03 | University Of South Florida | Compositions, méthodes d'utilisation et méthodes de traitement |
| JP6296985B2 (ja) | 2011-10-14 | 2018-03-20 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | うつ病及び神経障害性疼痛の治療における（２ｒ，６ｒ）−ヒドロキシノルケタミン、（ｓ）−デヒドロノルケタミン及び他の（ｒ，ｓ）−ケタミンの立体異性デヒドロ及びヒドロキシル化代謝生成物の使用 |
| MX354547B (es) | 2011-11-14 | 2018-03-09 | Alfasigma Spa | Ensayos y métodos para seleccionar un regimen de tratamiento para un sujeto con depresión. |
| US20130209585A1 (en) | 2012-02-13 | 2013-08-15 | Stanley Kim | Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy |
| PE20141906A1 (es) * | 2012-03-12 | 2014-12-05 | Janssen Pharmaceutica Nv | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento |
| AU2016203771A1 (en) | 2012-03-13 | 2016-06-23 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
| JP2015512418A (ja) | 2012-03-30 | 2015-04-27 | ザ ジェネラル ホスピタル コーポレイション | うつ病の治療におけるスコポラミンおよびケタミンを含む組成物 |
| WO2014020155A1 (fr) | 2012-08-02 | 2014-02-06 | Clinpharm Reform Gmbh | Formes d'administration transmuqueuse orale de kétamine s |
| US20140057988A1 (en) | 2012-08-23 | 2014-02-27 | Stuart WEG | Anxiolytic composition, formulation and method of use |
| FR2994844B1 (fr) | 2012-08-31 | 2015-01-02 | Assist Publ Hopitaux De Paris | Formulation gelifiante a base de ketamine |
| NZ619257A (en) | 2012-10-08 | 2015-07-31 | Auckland Uniservices Ltd | Ketamine derivatives |
| ES2484068B1 (es) | 2013-02-08 | 2015-04-16 | Ana MÍNGUEZ MARTÍ | Una composición farmacéutica que contiene ketamina y amitriptilina |
| JP6462663B2 (ja) | 2013-04-12 | 2019-01-30 | アイカーン スクール オブ メディシン アット マウント シナイ | 心的外傷後ストレス障害を処置するための方法 |
| WO2015031410A1 (fr) | 2013-08-26 | 2015-03-05 | Amorsa Therapeutics, Inc. | Dose orale à couche unique de kétamine neuro-atténuante |
| DK3043785T3 (da) | 2013-09-13 | 2021-11-15 | Univ Chiba Nat Univ Corp | Anvendelse af r-ketamin og salt deraf som lægemidler |
| CN103705909A (zh) | 2013-12-16 | 2014-04-09 | 陈镜伊 | 一种无痛人流用药 |
| WO2015101693A1 (fr) | 2013-12-31 | 2015-07-09 | Servicio Andaluz De Salud | Compositions et préparations combinées pour le traitement des douleurs oropharyngées |
| WO2015108985A1 (fr) | 2014-01-14 | 2015-07-23 | Children's Hospital Medical Center | Compositions comprenant de la kétamine pour le traitement d'un trouble du spectre de l'autisme |
| ES2743699T3 (es) | 2014-04-17 | 2020-02-20 | Develco Pharma Schweiz Ag | Forma de dosificación oral de ketamina |
| EP3151684B1 (fr) | 2014-05-04 | 2018-09-26 | Firmenich SA | Produits d'aliments et de boissons aromatisés |
| FR3023188B1 (fr) | 2014-07-04 | 2016-08-19 | Aptar France Sas | Dispositif de distribution de produit fluide. |
| MX2017001908A (es) | 2014-08-13 | 2017-08-08 | Janssen Pharmaceutica Nv | Metodo para el tratamiento de la depresion. |
| CA2961208A1 (fr) * | 2014-09-15 | 2016-03-24 | Janssen Pharmaceutica Nv | Regimes posologiques specifiques au genotype val66met (snp rs6265) et methodes pour le traitement de la depression |
| US20180015054A1 (en) | 2014-12-31 | 2018-01-18 | Icahn School Of Medicine At Mount Sinai | Method of Maintaining the Anti-Depressant Effect of Ketamine With Lithium |
| CN104798728A (zh) | 2015-05-08 | 2015-07-29 | 南京中医药大学 | 产后抑郁动物模型的建立方法及其应用 |
| US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| US20160338977A1 (en) | 2015-05-20 | 2016-11-24 | Janssen Pharmaceutica Nv | Methods and kits for treating depression |
| CN107847469A (zh) | 2015-06-27 | 2018-03-27 | 美国神农制药责任有限公司 | 氯胺酮透皮递送系统 |
| US20180296478A1 (en) | 2016-02-12 | 2018-10-18 | Synergistic Therapeutics, Llc | Sublingual antidepressant and antianxiety tablet |
| US20180042936A1 (en) | 2016-03-18 | 2018-02-15 | Genomind, Inc. | Maintenance therapy using tianeptine |
| CN117531017A (zh) | 2017-12-22 | 2024-02-09 | 詹森药业有限公司 | 用于治疗抑郁症的艾司氯胺酮 |
-
2018
- 2018-12-18 CN CN202311355796.8A patent/CN117531017A/zh active Pending
- 2018-12-18 BR BR112020012473-7A patent/BR112020012473A2/pt unknown
- 2018-12-18 JO JOP/2020/0156A patent/JOP20200156A1/ar unknown
- 2018-12-18 KR KR1020207021196A patent/KR20200113197A/ko not_active Application Discontinuation
- 2018-12-18 CA CA3086478A patent/CA3086478A1/fr active Pending
- 2018-12-18 KR KR1020247000937A patent/KR20240011237A/ko not_active Application Discontinuation
- 2018-12-18 US US16/956,403 patent/US11707440B2/en active Active
- 2018-12-18 JP JP2020534520A patent/JP2021506924A/ja active Pending
- 2018-12-18 SG SG11202005896WA patent/SG11202005896WA/en unknown
- 2018-12-18 MX MX2020006650A patent/MX2020006650A/es unknown
- 2018-12-18 CN CN201880090058.6A patent/CN112423789A/zh active Pending
- 2018-12-18 WO PCT/US2018/066143 patent/WO2019126108A1/fr active Application Filing
- 2018-12-21 EP EP18215651.3A patent/EP3501542A1/fr active Pending
- 2018-12-21 TW TW107146335A patent/TWI843711B/zh active
- 2018-12-21 TW TW112130258A patent/TW202415363A/zh unknown
- 2018-12-21 AU AU2018282466A patent/AU2018282466A1/en active Pending
- 2018-12-21 MA MA047719A patent/MA47719A/fr unknown
-
2020
- 2020-06-18 PH PH12020500555A patent/PH12020500555A1/en unknown
- 2020-06-18 IL IL275482A patent/IL275482A/en unknown
- 2020-07-13 MX MX2023012450A patent/MX2023012450A/es unknown
-
2023
- 2023-07-05 US US18/347,393 patent/US20240000728A1/en active Pending
- 2023-10-06 JP JP2023174444A patent/JP2024001204A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018282466A1 (en) | 2019-07-11 |
| RU2020123893A3 (fr) | 2022-04-29 |
| TWI843711B (zh) | 2024-06-01 |
| JOP20200156A1 (ar) | 2022-10-30 |
| BR112020012473A2 (pt) | 2020-11-24 |
| KR20200113197A (ko) | 2020-10-06 |
| US20210386688A1 (en) | 2021-12-16 |
| JP2024001204A (ja) | 2024-01-09 |
| CN112423789A (zh) | 2021-02-26 |
| IL275482A (en) | 2020-08-31 |
| CA3086478A1 (fr) | 2019-06-27 |
| PH12020500555A1 (en) | 2021-05-17 |
| US11707440B2 (en) | 2023-07-25 |
| TW202415363A (zh) | 2024-04-16 |
| EP3501542A1 (fr) | 2019-06-26 |
| US20240000728A1 (en) | 2024-01-04 |
| KR20240011237A (ko) | 2024-01-25 |
| TW201940162A (zh) | 2019-10-16 |
| WO2019126108A1 (fr) | 2019-06-27 |
| RU2020123893A (ru) | 2022-01-24 |
| MA47719A (fr) | 2020-01-15 |
| JP2021506924A (ja) | 2021-02-22 |
| MX2020006650A (es) | 2020-11-06 |
| MX2023012450A (es) | 2023-10-31 |
| CN117531017A (zh) | 2024-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275482A (en) | Asketamine for the treatment of depression | |
| IL279627A (en) | A method for treating depression | |
| IL269371A (en) | Treatment methods | |
| GB201707153D0 (en) | Therapy | |
| GB201608885D0 (en) | Treatment | |
| HK1258276A1 (zh) | 用於治療hiv的化合物和組合 | |
| IL283948A (en) | Methods for treating depression | |
| GB201813876D0 (en) | Treatment | |
| GB201719646D0 (en) | Therapy | |
| GB201708663D0 (en) | Therapy | |
| GB201813986D0 (en) | Coffins | |
| HK1257272A1 (zh) | 治療hiv的工具 | |
| IL286000A (en) | Asketamine for the treatment of depression | |
| HK1247558A1 (zh) | 塞內可瑞偉洛克(cenicriviroc)用於治療纖維化 | |
| GB201800546D0 (en) | Treatment | |
| PL3448340T3 (pl) | Pomocniczy element aplikacyjny do opatrywania ran | |
| PL3484475T3 (pl) | 1-Metylonikotynamid do leczenia choroby układu krążenia | |
| EP3145525A4 (fr) | Utilisation de microperoxidases pour le traitement de la carboxyhémoglobinémie | |
| IL272658A (en) | Surface treatment | |
| ZA201906319B (en) | Methods of treating depression | |
| GB201718985D0 (en) | Treatment | |
| ZA201805215B (en) | Preparation for nasal-nasopharyngeal treatment | |
| GB201713650D0 (en) | Treatment | |
| GB201814905D0 (en) | Treatment | |
| GB201706955D0 (en) | Treatment |